According to a new research report “Post-Operative Pain Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, post-operative pain therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.
Post-Operative Pain Therapeutics Pipeline Insights
Post-operative pain is a very common problem experienced by patients who undergo surgical procedures. Pain is an unpleasant sensory and emotional experience caused by any injury, disease, or surgical procedure. Pain can be acute or chronic, depending upon the time it lasts. Acute pain is an unpleasant sensory, and emotional and mental sensation, which usually lasts for several hours to days, rarely more than a month. Postoperative pain is a typical example of acute pain. Whereas, chronic pain usually lasts longer than six months.
Opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the medications used to treat post-operative pain. EXPAREL (by Pacira Pharmaceutical Inc.) is being the marketed drug for the treatment of post-operative pain.
Insights on Pipeline Segments
According to the research findings, majority of the pipeline drug candidates are being developed to be administered by oral route. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for post-operative pain through oral route has shown promising results in clinical studies.
Positive Clinical Trial Results are Expected to Drive the Post-Operative Pain Therapeutics Pipeline Advancements
Companies that are involved in developing therapeutics for post-operative pain have shown positive clinical results in the various phases of drug development. For instance, HTX-011 is being developed by Heron Therapeutics Inc. to prevent post-operative pain. The top-line results from phase II study of HTX-011 in patients with post-operative pain showed that the drug candidate was able to reduce pain intensity through 96 hours after bunion surgery and through 48 hours after hernia surgery.
Browse Detailed Report at:https://www.pharmaproff.com/report/post-operative-pain-therapeutics-pipeline-analysis
Strategic Developments Support the Post-Operative Pain Therapeutics Pipeline Growth
In June 2015, Elite Pharmaceuticals Inc. and Epic Pharma LLC entered into a sales and distribution agreement for the drug candidate, ELI-200, an abuse-deterrent opioid, for the treatment of adults with moderate to severe post-operative pain. Under the terms of agreement, Elite Pharmaceuticals Inc. will be responsible for the development of the drug candidate and Epic Pharma LLC will be responsible for its commercialization.
Elite Pharmaceuticals Inc., Epic Pharma LLC, Akorn Inc., Heron Therapeutics Inc., DURECT Corporation, and Cara Therapeutics Inc. are some of the major players involved in the development of therapeutics for the treatment of post-operative pain.
Post-Operative Pain Therapeutics Pipeline Analysis
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of post-operative pain. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the post-operative pain therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to post-operative pain.